Sunitinib, a Receptor Tyrosine Kinase Inhibitor, Increases Blood Pressure in Rats without Associated Changes in Cardiac Structure and Function

Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib

(2017) M. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

(2009) Joshua Ö. Haznedar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

(2009) Francisco Robert et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Heart failure associated with sunitinib malate

(2008) Aarif Y. Khakoo et al.   CANCER

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

(2008) J. O. Curwen et al.   CLINICAL CANCER RESEARCH

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

(2008) Shem Patyna et al.   TOXICOLOGIC PATHOLOGY

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

(2008) Yvonne Will et al.   TOXICOLOGICAL SCIENCES

Sunitinib-related cardiotoxicity: an interdisciplinary issue

(2008) Michael S Ewer et al.   Nature clinical practice. Cardiovascular medicine

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

(2007) J.-J. Mourad et al.   ANNALS OF ONCOLOGY